American Society of Clinical Oncology
ASCO
The ASCO Annual Meeting being held in June 3 to 7 will introduce hundreds of posters, abstracts and presentations of cancer studies, preclinical and clinical. BioSpace looks at three presenters.
The American Society of Clinical Oncology meeting will be underway next week in Chicago, and companies are preparing to share data from their pipelines. Here’s a look.
Two therapies for different cancers are moving forward in development following positive outcomes in their clinical trials ahead of the ASCO’s annual meeting in early June 2022.
The American Society of Clinical Oncology and the Association of Community Cancer Centers are combining their efforts to increase racial and ethnic diversity in clinical trials.
With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.
The tool developed by On Target boosts the ability of surgeons to find and remove cancerous lesions during surgical procedures, increasing progression free and overall survival.
Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.
Bayer, like many biopharma companies, is presenting study results at the 2021 American Society of Clinical Oncology (ASCO) Annual meeting being held online June 4-8, 2021.
PRESS RELEASES